Medtronic PLC
Medtronic PLC (MDT) is a leading global medical-technology company that designs, manufactures and sells a wide range of devices and therapies across cardiac, vascular, diabetes, neurological and spinal markets. Its portfolio includes pacemakers, insulin pumps, neurostimulation systems, spinal implants and surgical tools, generating a mix of implanted-device revenue and recurring consumables. With a market capitalisation of about $122.91bn, Medtronic benefits from ageing populations, steady demand for long-lived devices and an ongoing pipeline of incremental innovations. Important investor considerations include regulatory scrutiny, reimbursement and pricing pressures, competition from peers and emerging entrants, and occasional litigation. The company has historically returned cash through dividends and buybacks, but future payouts depend on cash flow and strategic priorities. This overview is general educational information only and not personalised investment advice; values can rise or fall and past performance is not a guarantee of future results.
Why It's Moving
Medtronic boosts shareholder returns with fresh dividend hike amid Hugo robot FDA win.
Medtronic declared a $0.71 per share cash dividend for Q3 fiscal 2026, approved on December 4, reinforcing its status as an S&P 500 Dividend Aristocrat with 48 straight years of increases. The company also secured FDA clearance for its Hugo robotic-assisted surgery system in key urologic procedures, signaling accelerated push into high-growth robotics.
- Dividend declaration maintains investor confidence in steady cash flows, building on May 2025 increase despite tariff headwinds potentially trimming results by $185M.
- Hugo RAS system cleared for prostatectomy, nephrectomy, and cystectomy, expanding Medtronic's robotics footprint in minimally invasive surgery.
- Recent momentum from strong Q2 beats—Cardiovascular up 10.8% to $3.436B, Diabetes +10.3%—underpins raised FY26 guidance of ~5.5% organic growth.
Medtronic boosts shareholder returns with fresh dividend hike amid Hugo robot FDA win.
Medtronic declared a $0.71 per share cash dividend for Q3 fiscal 2026, approved on December 4, reinforcing its status as an S&P 500 Dividend Aristocrat with 48 straight years of increases. The company also secured FDA clearance for its Hugo robotic-assisted surgery system in key urologic procedures, signaling accelerated push into high-growth robotics.
- Dividend declaration maintains investor confidence in steady cash flows, building on May 2025 increase despite tariff headwinds potentially trimming results by $185M.
- Hugo RAS system cleared for prostatectomy, nephrectomy, and cystectomy, expanding Medtronic's robotics footprint in minimally invasive surgery.
- Recent momentum from strong Q2 beats—Cardiovascular up 10.8% to $3.436B, Diabetes +10.3%—underpins raised FY26 guidance of ~5.5% organic growth.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Medtronic's stock with a target price of $108.82, indicating potential growth.
Financial Health
Medtronic is producing strong revenue, healthy profits, and solid cash flow, indicating good performance.
Dividend
Medtronic's average dividend yield of 2.79% makes it a reasonable choice for dividend-seeking investors. If you invested $1000 you would be paid $27.90 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring MDT
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketNovo Nordisk Stock Risks: Healthcare Diversification
As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.
Published: September 23, 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: September 22, 2025
Explore BasketJohnson & Johnson (Healthcare Diversification)
As Nigeria's population seeks stable growth opportunities, the global healthcare sector offers a compelling theme for portfolio diversification. This basket provides exposure through a collection of US and EU-listed industry leaders in pharmaceuticals, medical devices, and consumer health.
Published: September 16, 2025
Explore BasketARK Innovation ETF: What's Next for Africa's Growth?
Africa's digital economy is rapidly expanding, creating demand for cutting-edge technologies in finance, healthcare, and energy. This basket offers potential exposure to US-listed companies leading the disruptive innovation trends that are shaping the continent's future.
Published: September 15, 2025
Explore BasketWearable Health Stocks: Growth Potential vs Competition
Apple's recent FDA clearance for its Apple Watch hypertension feature marks a major step in wearable medical technology. This development opens up investment opportunities in the broader ecosystem of connected health devices and remote patient monitoring services.
Published: September 12, 2025
Explore BasketAt-Home Healthcare Stocks Explained | FDA Approval
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug simplifies treatment and reduces the need for hospital visits. This development highlights a broader trend toward at-home care, creating potential investment opportunities in companies that provide related medical devices and healthcare services.
Published: August 30, 2025
Explore BasketWearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: August 21, 2025
Explore BasketHealthcare's Compliance Catalyst
The Department of Justice's investigation into UnitedHealth's billing practices is increasing pressure on the entire healthcare industry to ensure compliance. This regulatory focus creates an investment opportunity in companies that provide specialized technology for transparent and accurate medical billing.
Published: July 26, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Steady implant demand
Implanted devices and related consumables can provide recurring revenue as populations age, though demand and pricing may vary across markets.
Global market reach
Sales span developed and emerging markets, offering diversification but exposing the company to currency and local reimbursement risks.
R&D-driven pipeline
Ongoing product development and approvals can drive long-term growth, although clinical outcomes and commercial uptake are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
